-
公开(公告)号:US20060127903A1
公开(公告)日:2006-06-15
申请号:US10525150
申请日:2003-08-20
申请人: Nuzhat Ahmed , Gregory Rice , Michael Quinn
发明人: Nuzhat Ahmed , Gregory Rice , Michael Quinn
CPC分类号: C12N9/1205 , A61K38/00 , C07K16/40 , C12Y207/10002 , G01N33/57488 , G01N2800/52
摘要: The present invention relates to a cell-free immunoreactive Integrin Linked Kinase which is present in samples of biological fluids from patients suffering from ovarian cancer. The invention also relates to methods of diagnosis, screening, monitoring treatment and treatment of cancers, especially ovarian cancer, and to kits and compounds for use therein.
摘要翻译: 本发明涉及存在于患有卵巢癌的患者的生物液体的样品中的无细胞免疫反应性整合素连接的激酶。 本发明还涉及诊断,筛选,监测治疗和治疗癌症,特别是卵巢癌的方法,以及用于其中的试剂盒和化合物。
-
42.
公开(公告)号:US20240139320A1
公开(公告)日:2024-05-02
申请号:US18547652
申请日:2022-02-23
发明人: Robbie G. Majzner , Aidan Tousley , Louai Labanieh , Crystal L. Mackall , Maria Caterina Rotiroti
IPC分类号: A61K39/00 , A61P35/00 , C07K14/705 , C07K14/725 , C07K14/73 , C07K16/32 , C12N5/0783 , C12N9/12 , C12N9/16
CPC分类号: A61K39/4631 , A61K39/4611 , A61K39/4644 , A61P35/00 , C07K14/7051 , C07K14/70514 , C07K14/70517 , C07K14/70521 , C07K16/32 , C12N5/0636 , C12N9/12 , C12N9/16 , C12Y207/10002 , C12Y301/04011 , C07K2317/31 , C07K2317/35 , C07K2319/02 , C07K2319/03
摘要: The present disclosure generally relates to, inter alia, chimeric antigen receptors (CARs) that contain an intracellular signaling domain without an immune receptor tyrosine based activation motif (ITAM). The disclosure also provides compositions and methods useful for producing such molecules, as well as methods for the detection and treatment of diseases, such as cancer.
-
公开(公告)号:US20230233606A1
公开(公告)日:2023-07-27
申请号:US17784408
申请日:2020-12-18
申请人: AUTOLUS LIMITED
发明人: Shaun Cordoba , Evangelia Kokalaki , Thomas Grothier , Shimobi Onuoha , Simon Thomas , Martin Pulé
IPC分类号: A61K35/17 , C12N9/12 , C12N5/0783 , C07K16/28 , C07K14/705 , C07K14/725
CPC分类号: A61K35/17 , C12N9/12 , C12Y207/10002 , C12N5/0636 , C07K16/2803 , C07K14/70578 , C07K14/7051 , C07K2317/622 , C07K2319/03 , C07K2319/33
摘要: The present invention provides cell which co-expresses a chimeric antigen receptor (CAR) and a dominant negative C-terminal Src kinase (dnCSK). The present invention also provides nucleic acid constructs, vectors and methods for making such a cell and the use of such a cell in the treatment of diseases such as cancer by adoptive immunotherapy.
-
公开(公告)号:US20180179260A1
公开(公告)日:2018-06-28
申请号:US15738467
申请日:2016-06-29
申请人: THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA , JOSLIN DIABETES CENTER, INC.
发明人: Michael S. Kuhns , Thomas Serwold
IPC分类号: C07K14/74 , C12N5/0783 , C07K14/725 , C12N9/12
CPC分类号: C07K14/70539 , A61K35/17 , C07K14/705 , C07K14/7051 , C07K2319/02 , C07K2319/03 , C07K2319/74 , C12N5/0636 , C12N9/12 , C12Y207/10002
摘要: Chimeric receptors featuring major histocompatibility molecules grafted onto T cell receptor molecules and surrogate co-receptors featuring cell surface receptor ligands fused with signaling molecule domains. The chimeric receptors can be used to redirect cells, altering their specificity. T cells expressing chimeric receptors may bind to ICRs of target T cells for which their chimeric receptors are specific. Surrogate co-receptors may be used to help enhance TCR-CD3 signaling as part of this modular receptor system. The chimeric receptors and surrogate coreceptors may be used to help eliminate autoreactive T cells or program T cells to desired effector functions.
-
公开(公告)号:US10004788B2
公开(公告)日:2018-06-26
申请号:US15851650
申请日:2017-12-21
IPC分类号: A61K38/45 , A61K48/00 , A61K38/17 , C12N15/86 , A61K49/00 , A61B3/032 , A61K35/761 , C12N7/00 , A61K45/06 , A61K31/7088 , C07K14/71 , C12N9/12 , C07K16/22 , C07K16/08 , A61K9/00 , A61K39/00
CPC分类号: A61K38/45 , A61B3/032 , A61K9/0048 , A61K31/7088 , A61K35/761 , A61K38/179 , A61K45/06 , A61K48/00 , A61K48/0075 , A61K49/0004 , A61K2039/505 , C07K14/71 , C07K16/081 , C07K16/22 , C07K2317/24 , C07K2317/55 , C07K2317/73 , C07K2319/32 , C12N7/00 , C12N9/12 , C12N15/86 , C12N2710/14044 , C12N2750/14141 , C12N2750/14142 , C12N2750/14143 , C12N2750/14171 , C12Y207/10 , C12Y207/10001 , C12Y207/10002 , A61K2300/00
摘要: The present disclosure provides compositions and methods for the prevention or treatment of ocular neovascularization, such as AMD, in a human subject, by administering subretinally a pharmaceutical composition comprising a pharmaceutically effective amount of a vector comprising a nucleic acid encoding soluble Fms-related tyrosine kinase-1 (sFlt-1) protein to the human subject.
-
公开(公告)号:US20180104186A1
公开(公告)日:2018-04-19
申请号:US15712294
申请日:2017-09-22
申请人: UNIVERSITY OF MIAMI
IPC分类号: A61K9/127 , A61P17/00 , A61K38/39 , A61K31/7088 , A61K38/21 , A61K38/18 , A61K38/20 , A61K38/45 , A61K35/28 , A61K35/16 , A61K35/22
CPC分类号: A61K9/127 , A61K9/0014 , A61K31/7088 , A61K35/16 , A61K35/22 , A61K35/28 , A61K38/1808 , A61K38/2033 , A61K38/204 , A61K38/21 , A61K38/39 , A61K38/45 , A61K45/06 , A61K47/46 , A61P17/00 , C12Y207/10002 , C12Y207/11024
摘要: The present invention provides compositions and methods for treating epidermolysis bullosa.
-
公开(公告)号:US09943573B2
公开(公告)日:2018-04-17
申请号:US14281749
申请日:2014-05-19
IPC分类号: A61K38/45 , A61K48/00 , A61K45/06 , A61K31/7088 , A61K38/17 , A61K35/761 , C07K14/71 , C12N9/12 , C07K16/08 , C07K16/22 , A61B3/032 , A61K49/00 , C12N7/00 , C12N15/86 , A61K9/00 , A61K39/00
CPC分类号: A61K38/45 , A61B3/032 , A61K9/0048 , A61K31/7088 , A61K35/761 , A61K38/179 , A61K45/06 , A61K48/00 , A61K48/0075 , A61K49/0004 , A61K2039/505 , C07K14/71 , C07K16/081 , C07K16/22 , C07K2317/24 , C07K2317/55 , C07K2317/73 , C07K2319/32 , C12N7/00 , C12N9/12 , C12N15/86 , C12N2710/14044 , C12N2750/14141 , C12N2750/14142 , C12N2750/14143 , C12N2750/14171 , C12Y207/10 , C12Y207/10001 , C12Y207/10002 , A61K2300/00
摘要: The present disclosure provides compositions and methods for the prevention or treatment of ocular neovascularization, such as AMD, in a human subject, by administering subretinally a pharmaceutical composition comprising a pharmaceutically effective amount of a vector comprising a nucleic acid encoding soluble Fms-related tyrosine kinase-1 (sFlt-1) protein to the human subject.
-
公开(公告)号:US09790475B2
公开(公告)日:2017-10-17
申请号:US14758339
申请日:2013-12-18
申请人: COVAGEN AG
发明人: Fabian Buller , Ulrich Wüllner , Irene Zbinden , Isabella Attinger-Toller , Ulrike Von Der Bey , Susann König-Friedrich , Julian Bertschinger , Dragan Grabulovski , Patricia Henne
IPC分类号: C07K14/00 , C12N9/12 , C07K14/765 , C07K14/47 , C07K16/18
CPC分类号: C12N9/12 , C07K14/47 , C07K14/765 , C07K16/18 , C07K2317/31 , C07K2319/31 , C12Y207/10002
摘要: The present invention relates to a polypeptide binding to human serum albumin and comprising or consisting of an amino acid sequence selected from the group consisting of: (a) GVTLFVALYDY(X1)(X2)(X3)(X4)(X5) (X6)D(X7)SFHKGEKFQIL(X8)(X9)(X10)(X11)(X12)G(X13)(X14)W(X15)(X16)RSLTTG(X17)(X18)G(X19)IPSNYVAPVDSIQ (SEQ ID NO: 1), wherein (X1) is A, V, I, L, M, G, P, S, T, N, Q, C, R, H, K, D or E; (X2) is R, H, K, A, V, I, L, M, G, P, S, T, N, Q or C; (X3) is R, H, K, S, T, N, Q, C, F, Y, W, A, V, I, L, M, G or P; (X4) is S, T, N, Q, C, A, V, I, L, M, G, P, R, H, K, F, Y, W, D or E; (X5) is S, T, N, Q, C, D, E, F, Y, W, A, V, I, L, M, G, P, R, H or K; (X6) is F, Y, W, A, V, I, L, M, G, P, R, H, K, S, T, N, Q or C; (X7) is A, V, I, L, M, G, P, R, H or K; (X8) is S, T, N, Q, C, D or E; (X9) is S, T, N, Q, C, D, E, A, V, I, L, M, G, P, F, Y or W; (X10) is A, V, I, L, M, G or P; (X11) is F, Y, W, R, H or K; (X12) is S, T, N, Q, C, F, Y or W; (X13) is F, Y, W, R, H, K, S, T, N, Q, C, D, E, A, V, I, L, M, G or P; (X14) is F, Y, W, A, V, I, L, M, G or P; (X15) is D, E, A, V, I, L, M, G or P; (X16) is A, V, I, L, M, G or P; (X17) is D, E, A, V, I, L, M, G, P, R, H or K; (X18) is S, T, N, Q, C, A, V, I, L, M, G or P; (X19) is F, Y, W, S, T, N, Q or C; and (b) an amino acid sequence which is at least 90% identical to the amino acid sequence of (a), wherein the identity determination excludes amino acid positions (X1) to (X19).
-
公开(公告)号:US20170290821A1
公开(公告)日:2017-10-12
申请号:US15511930
申请日:2015-09-18
IPC分类号: A61K31/473 , A61K31/519 , C12N15/113 , C12Q1/68 , C12Q1/48
CPC分类号: A61K31/473 , A61K31/519 , A61K31/713 , A61K45/00 , C07K14/47 , C07K2319/43 , C12N9/12 , C12N15/09 , C12N15/1137 , C12N2310/14 , C12N2760/16111 , C12N2760/16122 , C12Q1/485 , C12Q1/68 , C12Q1/6876 , C12Y207/10002 , G01N33/50 , G01N33/5023 , G01N2333/11 , G01N2500/10
摘要: The present invention provides an anti-influenza virus agent that targets biomolecules of host cells including human cells and a method of screening a candidate molecule for the anti-influenza virus agent. That is, the present invention is an anti-influenza virus agent that has an effect of suppressing expression or a function of a gene that encodes a protein having an effect of suppressing incorporation of an influenza virus vRNA or an NP protein into influenza virus-like particles in host cells and the gene is at least one selected from the group including JAK1 gene and the like.
-
公开(公告)号:US20170281768A1
公开(公告)日:2017-10-05
申请号:US15454769
申请日:2017-03-09
申请人: Covagen AG
发明人: Simon Sebastian BRACK , Frédéric MOURLANE , Isabella TOLLER , Richard WOODS , Julian BERTSCHINGER , Dragan GRABULOVSKI , Babette SCHADE , Kristina KLUPSCH , Helen HACHEMI
IPC分类号: A61K39/395
CPC分类号: C12N9/12 , A01K67/0278 , A01K2227/105 , A01K2267/01 , A61K39/39591 , A61K2039/505 , C07K16/30 , C07K16/32 , C07K2317/31 , C07K2317/73 , C07K2317/77 , C07K2317/90 , C07K2318/20 , C07K2319/00 , C07K2319/30 , C12Y207/10002
摘要: The present invention relates to a binding molecule that specifically binds to two different epitopes of an antigen expressed on tumor cells, wherein the binding molecule comprises: (a) a first binding (poly)peptide that specifically binds to a first epitope of said antigen expressed on tumor cells, wherein said first binding (poly)peptide is a Fyn SH3-derived polypeptide; and (b) a second binding (poly)peptide that specifically binds to a second epitope of said antigen expressed on tumor cells. The present invention further relates to a nucleic acid molecule encoding the binding molecule of the invention, a vector comprising said nucleic acid molecule as well as a host cell or a non-human host transformed with said vector. The invention further relates to a method of producing a binding molecule of the invention as well as to pharmaceutical and diagnostic composition. Moreover, the present invention also relates to the binding molecule, the nucleic acid molecule, the vector or the host cell of the invention for use in the treatment of tumors.
-
-
-
-
-
-
-
-
-